Aptus Pharma Ltd

Aptus Pharma Limited will hold a board meeting on Tuesday, October 20, 2026, to consider and approve the unaudited financial results for the half year ended September 30, 2026, and to take on record the limited review report thereon; the trading window for the company's securities has been closed from October 1, 2026, and will remain closed until 48 hours after the declaration of the financial results.

Accurate Securities & Registry Private Limited, a Category I Registrar and Share Transfer Agent recognized as Gujarat’s No. 1 in its field, is located at 1105-1108, K P Epitome, Ahmedabad. The company, with Corporate Identification Number U74900GJ2013PTC077829, provides services related to share issuance and transfer management. Investors and clients can reach Accurate Securities at +91-79-48000319, via email at investor@accuratesecurities.com, or through their website, www.accuratesecurities.com. Operational hours are Monday to Friday from 11:30 AM to 5:00 PM, with a lunch break from 1:30 PM to 2:30 PM. The company’s INR number is INR000004173.

Aptus Pharma Limited informed the BSE that the trading window for dealing in the company's securities will be closed from October 01, 2026, until 48 hours after the declaration of financial results for the half year ended September 30, 2026, in accordance with the company’s insider trading code.

Aptus Pharma Limited will hold a board meeting on August 17, 2026, to consider a valuation report for a preferential issue of 16,10,100 equity shares, determine an issue price based on a valuation report from a registered valuer, and take record of a PCS certificate confirming compliance with ICDR and Companies Act, 2013 provisions. The company will also convene its 16th Annual General Meeting on September 14, 2026, via video conferencing and approve the notice for the meeting. Trading window for designated persons and their immediate relatives will be closed from August 12, 2026, at 6:00 p.m. until 48 hours after the board meeting outcome is disseminated.

Aptus Pharma Limited will seek to raise funds through the issuance of equity shares and/or other eligible securities via a preferential allotment, according to a regulatory filing with the BSE Ltd on August 5, 2026. The company’s board of directors will consider and deliberate on the proposal during a meeting scheduled for August 8, 2026, and the trading window for company securities will be closed for designated persons and their immediate relatives from August 5, 2026, at 6:00 p.m. until 48 hours after the board meeting’s outcome is disseminated to the stock exchanges.

Aptus Pharma will hold a meeting of the Board of Directors of the Company on 12 June 2026.

Aptus Pharma will hold a meeting of the Board of Directors of the Company on 27 April 2026.

Aptus Pharma will hold a meeting of the Board of Directors of the Company on 24 March 2026.Powered by Capital Market - Live

Shares of Aptus Pharma surged 23.89% in ten trading sessions from its recent closing low of Rs 169.50 on 31 December 2025. The stock hit an all-time high of Rs 210 today. On the BSE, 0.36 lakh shares have been traded so far, compared with an average daily volume of 0.50 lakh shares over the past two weeks. The stock had outperformed the market over the past month, rising 29.63% as against the Sensex's 0.88% drop. The stock had outperformed the market over the three months, rising 137.77% as against the Sensex's 3.15% jump. On the technical front, the stock's daily RSI (relative strength index) stood at 83.352. The RSI oscillates between zero and 100. Traditionally, the RSI is considered overbought when above 70 and oversold when below 30. On the daily chart, the stock was trading above its 50-day, 100-day, and 200-day simple moving average (SMA), placed at 80.80, 77.33, and 42.35, respectively. These levels will act as crucial support zones in the near term. Aptus Pharma is engaged in the business of marketing and distribution of finished pharmaceutical formulations. The company's consolidated net profit surged 270% to Rs 2.96 crore on a 37.5% jump in net sales to Rs 24.56 crore in FY26 over FY25.Powered by Capital Market - Live

Aptus Pharma will hold a meeting of the Board of Directors of the Company on 10 November 2025.Powered by Capital Market - Live